Morris B J, Hunt S P
MRC Molecular Neurobiology Unit, MRC Centre, Cambridge, U.K.
Neurosci Lett. 1991 Apr 29;125(2):201-4. doi: 10.1016/0304-3940(91)90028-r.
Rats were treated for 3 days with the selective D1 dopamine receptor antagonist SCH23390 (250 micrograms/kg i.p., 3 x daily), the selective D2 dopamine receptor antagonist YM-09151-M (500 micrograms/kg i.p., 2 x daily), or saline. The levels of striatal proenkephalin mRNA were then assayed by in-situ hybridisation histochemistry, using a synthetic oligonucleotide probe. Following YM-09151-M treatment, proenkephalin mRNA levels were dramatically raised in the striatum, compared to animals receiving vehicle injections. In contrast, rats treated with SCH23390 showed decreased striatal levels of proenkephalin mRNA. The results demonstrate that selective D2 receptor blockade leads to enhanced proenkephalin gene expression in rat striatum, while selective D1 receptor antagonism has the opposite effect.
用选择性D1多巴胺受体拮抗剂SCH23390（腹腔注射250微克/千克，每日3次）、选择性D2多巴胺受体拮抗剂YM-09151-M（腹腔注射500微克/千克，每日2次）或生理盐水对大鼠进行3天治疗。然后使用合成寡核苷酸探针，通过原位杂交组织化学法测定纹状体前脑啡肽原mRNA的水平。与接受载体注射的动物相比，用YM-09151-M治疗后，纹状体中的前脑啡肽原mRNA水平显著升高。相反，用SCH23390治疗的大鼠纹状体前脑啡肽原mRNA水平降低。结果表明，选择性阻断D2受体可导致大鼠纹状体中前脑啡肽原基因表达增强，而选择性拮抗D1受体则产生相反的效果。
